Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Neoplasms 7Prostatic Neoplasms 5Brain Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Radiation Injuries 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hemangioma 2Breast Neoplasms 2Urogenital Neoplasms 1Scleroderma, Localized 1Respiratory Distress Syndrome 1Radiation Pneumonitis 1Popliteal Cyst 1Polycystic Ovary Syndrome 1Pneumonia, Viral 1Pneumonia 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Optic Neuritis 1Neurodermatitis 1Neoplastic Cells, Circulating 1Neoplasms, Fibrous Tissue 1Neoplasms, Connective and Soft Tissue 1Neoplasms, Connective Tissue 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Nasopharyngeal Carcinoma 1

Interventions

Rituximab 416Cyclophosphamide 348Vincristine 173Prednisone 172Doxorubicin 168Etoposide 160Peripheral Blood Stem Cell Transplantation 114Filgrastim 108Lenalidomide 97fludarabine phosphate 96Radiotherapy 80Cytarabine 80Gemcitabine 73Melphalan 66Mycophenolic Acid 64Cyclosporine 60Methotrexate 59Busulfan 57Ifosfamide 55Carmustine 55fludarabine 50Tacrolimus 50Whole-Body Irradiation 49Carboplatin 49polatuzumab vedotin 44Oxaliplatin 44Dexamethasone 44Antilymphocyte Serum 42ibrutinib 40Bendamustine Hydrochloride 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × Adrenal Cortex Hormones × Clear all
NCT03003520 2023-05-22

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Celgene

Phase 2 Completed
46 enrolled 20 charts
LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡